ELVN logo

ENLIVEN THERAPEUTICS INC

ELVNNASDAQ
🏆 #1624 by market capEarnings Nov 10US Equity
$46.53▲ $0.52 (+1.11%)
Market closed · at close
🔔
Track ELVN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.1%
7d▲ 0.9%
14d▼ 5.3%
30d▼ 19.7%
ytd▲ 202.3%
1y▲ 127.1%
🏦Market Cap
$3.32B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$46.26 – $46.94
52-Week Range
$14.79 – $62.32
Volume
$1.72B
Avg Volume
$2.12B
Shares Outstanding
71.4M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$519M
Last Q Revenue
$122M
P/E Ratio
-28.1
P/S Ratio
0.0x
EPS (TTM)
$-1.60
Dividend Yield
0.00%
Dilution (1yr)
+13.7%

Why Investors Own ELVN

  • ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 49% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ELVN logo

ENLIVEN THERAPEUTICS INC

ELVN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$120M▲ +14.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$70M▼ −3.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
56.7M▲ +13.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$98M▼ −$26M YoY
StockOtter · stockotter.space

About ENLIVEN THERAPEUTICS INC

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$46.70
▲ +0.4% Upside
High Target$52.64
Low Target$43.48
Based on 15 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

ENLIVEN THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ELVN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ENLIVEN THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.